Aevum Zenth's Health Sciences division is dedicated to developing breakthrough therapies for low-prevalence conditions. Leveraging our AI-driven discovery platform, genomic analytics, and advanced delivery systems, we accelerate cures for patients with limited options.
This pipeline overview includes forward-looking statements regarding our development programs. Clinical development involves significant risks, and there is no guarantee that any asset will successfully complete clinical trials or receive regulatory approval. All data reflects information available as of Q4 2025.